Publish Data: February 2013 Report Format: PDF
Global Markets Direct’s, 'Liver Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cancer. Liver Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
A snapshot of the global therapeutic scenario for Liver Cancer.
A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Liver Cancer pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.
Reasons to Buy
Identify and understand important and diverse types of therapeutics under development for Liver Cancer.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
3 Liver Cancer Snapshot
3.1 Business Description
4 Liver Cancer- Research and Development Overview
4.1 Key Therapeutic Areas
5 Liver Cancer- Pipeline Review
5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities
6 Liver Cancer Pipeline Products Glance
6.1 Liver Cancer Phase II Pipeline
6.2 Liver Cancer Phase I Pipeline
6.3 Liver Cancer Pre-Clinical Pipeline
7 Liver Cancer - Drug Profiles
7.1 Product 1
7.1.1 Product Description
7.1.2 Mechanism of Action
7.1.3 R&D Progress
8 Liver Cancer Pipeline Analysis
8.1 Liver Cancer Pipeline Products by Therapeutic Class
8.2 Liver Cancer Pipeline Products by Target
8.3 Liver Cancer Pipeline by Route of Administration
8.4 Liver Cancer Pipeline Products by Molecule Type
9 Liver Cancer- Recent Pipeline Updates
10 Liver Cancer- Dormant Pipeline Projects
10.1 Feature on Dormant Projects
11 Liver Cancer- Discontinued Pipeline Products
11.1 Discontinued Pipeline Product Profiles
11.1.1 Product 1
12 Liver Cancer – Featured News
13 Liver Cancer Statement
13.1 Liver Cancer - Locations and Subsidiaries
14.1 Global Markets Direct Research Methodology
14.3 Secondary Research
14.4 Primary Research
14.6 Expert Panels
14.7 Contact Us
List of Figures
1.2 List of Figures
Figure 1: Liver Cancer - Research and Development Overview
Figure 2: Liver Cancer - Pipeline by Stage of Development, 2013
Figure 3: Liver Cancer - Monotherapy Products in Pipeline, 2013
Figure 4: Liver Cancer - Combination Treatment Modalities in Pipeline, 2013
Figure 5: Liver Cancer - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Liver Cancer - Pipeline By Therapeutic Class
Figure 7: Liver Cancer - Pipeline By Target and Stage of Development
Figure 8: Liver Cancer - Pipeline By Target
Figure 9: Liver Cancer - Pipeline By Route of Administration and Stage of Development
Figure 10: Liver Cancer - Pipeline By Route of Administration
Figure 11: Liver Cancer - Pipeline By Molecule Type and Stage of Development
Figure 12: Liver Cancer - Pipeline By Molecule Type
List of Tables
1.1 List of Tables
Table 1: Liver Cancer - Key Information
Table 2: Liver Cancer - Key Facts
Table 3: Liver Cancer - Key Therapeutic Areas
Table 4: Liver Cancer - Pipeline by Stage of Development, 2013
Table 5: Liver Cancer - Monotherapy Products in Pipeline, 2013
Table 6: Liver Cancer - Combination Treatment Modalities in Pipeline, 2013
Table 7: Liver Cancer - Phase II Pipeline, 2013
Table 8: Liver Cancer - Phase I Pipeline, 2013
Table 9: Liver Cancer - Pre-Clinical Pipeline, 2013
Table 10: Liver Cancer - Pipeline By Therapeutic Class
Table 11: Liver Cancer - Pipeline By Target
Table 12: Liver Cancer - Pipeline By Route of Administration
Table 13: Liver Cancer - Pipeline By Molecule Type
Table 14: Liver Cancer - Recent Pipeline Updates
Table 15: Liver Cancer - Dormant Pipeline Projects